Second-tier Pharmaceutical Companies PDF Download

Author: Hans F. Mohr
Publisher:
ISBN: 9781860674334
Category : Pharmaceutical industry
Languages : en
Pages : 176

View

Book Description

Author: Karen Beynon
Publisher: Woodhead Publishing
ISBN: 9781855734586
Category : Business & Economics
Languages : en
Pages : 188

View

Book Description
The pharmaceutical sector offers some of the most exciting financial and business opportunities today. This essential and practical guide gives you all the tools you need to assess such opportunities. The second edition of the respected Pharmaceutical Equities, it has been thoroughly revised and updated to reflect the changes, especially in life sciences, since the first edition. The book is international in outlook, and explains the rules of the game not just for wise investing, but also for understanding how this uniquely complex and highly regulated business works. The authors explain: HOW to evaluate the technology and research and development, as well as the sales potential of ensuing products WHAT key issues will affect and influence companies in the next few years HOW to balance potential high returns on breakthrough products against accompanying risks The book begins with a look at the global pharmaceutical industry, from its history to the structure of present day companies. The second part explores how to analyse and value pharmaceutical and biotechnology companies. The final part deals with trading itself and looks at share price movement and the main equity markets throughout the world. Both practical and comprehensive, this handbook will be essential reading for investors, analysers and corporate planners - and is the ONLY book which will show you how to actually value pharmaceutical companies.

Author: Stephen A Sheller
Publisher:
ISBN: 9781947492561
Category : Art
Languages : en
Pages : 148

View

Book Description
UPDATED AND REVISED EDITION: Throughout his distinguished legal career, Stephen Sheller has relished the role of the underdog, evincing a sharply honed sense of fair play and justice. Early in his career, he represented Black Panthers in Philadelphia when they were arrested on trumped up murder and conspiracy charges. Later, he was in the vanguard of lawyers who took on the tobacco industry in the 1990s and he reprised that strategy a few years later in targeting Big Pharma for its harmful products and their deleterious effects on public health. In Big Pharma, Big Greed The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health Sheller tells a tale that is at once deeply personal but also with wide repercussions for the U.S. health care system and the hundreds of millions of Americans whose lives literally depend on it. Decades of litigating against the pharmaceutical industry taught Sheller one irreducible lesson: In too many instances, unneeded and at times dangerous drugs are foisted on the public without adequate warning as to risks, all in the service of boosting industry profits. All too often, achieving block buster status for a patent protected medication becomes an end in itself, as Big Pharma companies manipulate clinical trial data, draft scholarly articles for friendly physicians often in their pay, and market their drugs for uses that never had been approved by the federal Food and Drug Administration. This last practice proved to be something of an Achilles Heel for the industry. In litigation that resulted in settlement and fines in the billions, companies such as Eli Lilly acknowledged marketing drugs off label to a broad range of patients for whom the medications had never been approved. Sheller's litigation formed the basis for these settlements and the effort is ongoing. He and other plaintiffs' lawyers now are suing Janssen Pharmaceuticals for the adverse impacts of its drug, Risperdal, a second generation anti-psychotic that Sheller and others allege is linked to the growth of female breast tissue in young boys and men. Already there have been several big jury verdicts against Janssen with hundreds of more cases yet to be tried. In the book, Sheller not only recounts his major litigation battles but also makes sweeping proposals for industry reform. To restore regulatory credibility, Sheller proposes that responsibility for testing new medicines be taken away from the industry and given over to hospitals and other public entities partnering with government regulators. Pharmaceutical companies that betray the public trust would risk government- initiated dissolution. Harsh medicine to be sure, but Sheller believes entirely appropriate to the underlying malady.

Author: Alfred D. Chandler Jr.
Publisher: Harvard University Press
ISBN: 0674029372
Category : Business & Economics
Languages : en
Pages : 379

View

Book Description
The dean of business historians continues his masterful chronicle of the transforming revolutions of the twentieth century begun in Inventing the Electronic Century. Alfred Chandler argues that only with consistent attention to research and development and an emphasis on long-term corporate strategies could firms remain successful over time. He details these processes for nearly every major chemical and pharmaceutical firm, demonstrating why some companies forged ahead while others failed. By the end of World War II, the chemical and pharmaceutical industries were transformed by the commercializing of new learning, the petrochemical and the antibiotic revolutions. But by the 1970s, chemical science was no longer providing the new learning necessary to commercialize more products, although new directions flourished in the pharmaceutical industries. In the 1980s, major drug companies, including Eli Lilly, Merck, and Schering Plough, commercialized the first biotechnology products, and as the twenty-first century began, the infrastructure of this biotechnology revolution was comparable to that of the second industrial revolution just before World War I and the information revolution of the 1960s. Shaping the Industrial Century is a major contribution to our understanding of the most dynamic industries of the modern era.

Author: Heike Mayer
Publisher: Edward Elgar Publishing
ISBN: 085793869X
Category : Business & Economics
Languages : en
Pages : 273

View

Book Description
Second tier high-tech regions are taking a different path than their well-known counterparts such as Silicon Valley or Route 128 around Boston. They may lack many prerequisites of growth such as a world-class research university or high levels of venture capital funding. Often, however, they can successfully leverage anchor firms and entrepreneurial spinoffs. This book explores the evolution of these regions in the United States. The author critically examines how they evolved as knowledge-based economies, how they leveraged entrepreneurship and innovation, and ultimately how they employed public policy to support economic growth. Filling a gap in the literature, the book speaks to researchers and policymakers across the fields of entrepreneurship, economic geography and economic development planning.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030904491X
Category : Medical
Languages : en
Pages : 225

View

Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.

Author: Yixuan Xiao
Publisher:
ISBN:
Category : Electronic dissertations
Languages : en
Pages : 144

View

Book Description
This dissertation focuses on drug distribution through Pharmacy Benefit Managers (PBMs) in the pharmaceutical supply chain. PBMs are companies like Express/Medco, CVS/Caremark, which are a very important part of the US healthcare market. They are the intermediaries between their clients (major corporations, government organizations, insurance companies etc.) and the rest of the pharmaceutical supply chain (drug manufacturers/wholesalers and pharmacies). PBMs help their clients control the drug cost of their plan through designing formularies for them and negotiating wholesale prices with drug manufacturers/wholesalers and reimbursement with pharmacies and other players in the supply chain. Given the importance and complexity of the pharmaceutical market, understanding the role of PBMs in the US healthcare system is critical for academicians and practitioners, as well as for policy makers. This dissertation develops a theoretical model that captures the complex role PBMs play in the financial flows of pharmaceutical supply chains. We study the competition among multiple Pharmacy Benefit Managers (PBMs) for the patronage of a client organization. Each PBM selects a list of prices to be charged to the client organization for each of the branded and generic drugs within a therapeutical class (price decision) and a formulary list that assigns branded drugs to preferred or non-preferred tiers (formulary decision). Drug manufacturers offer rebates to PBMs for drugs on preferred tier of formularies. The individuals participating in the client's pharmacy benefit plan are the ones consuming the drugs and making purchasing decisions, while the client organization is paying the majority of drug cost. The choices of the individuals and the client organization are governed by different utility measures. For this complex drug distribution setting and for competing PBMs, we show the existence and uniqueness of a pure Nash equilibrium on aggregate price and formulary decisions. Moreover, the formulary list for each PBM is a dominant choice, in the sense that it is optimal irrespective of the choices made by the competing PBMs. We characterize each PBM's optimal formulary and equilibrium price decisions, and discuss the impact of various model primitives on these decisions. As an application of our model, we use it to gain insights on the impact of mergers in the PBM industry for both PBMs and the client. Finally, we extend our base model to the more general setting of multiple client organizations, each with drugs from multiple therapeutical classes. We investigate the competition among branded drug manufacturers when their drugs are distributed through a common PBM. The PBM administers a prescription drug benefit program for its clients, and to the individuals who participate in the PBM's plan. We model the interactions among drug manufacturers and the PBM as a two-stage game. In the first stage, pharmaceutical companies simultaneously set prices and rebates for their products charged to the PBM; In the second stage, the PBM develops a standardized formulary for the plan enrollees on behalf of their clients, which specifies the copayment for each drug. When designing the health plan formulary for its clients, a PBM needs to consider not only controlling the cost of the drugs consumed under the plan, but also the consumer welfare of the participants enrolled in its pharmacy benefit plan. Such concern is due to a PBM's commitment to its clients to provide long-term quality benefit for the plan beneficiaries, winning potential clients from competing PBMs/healthcare plans, and the need for regulatory approvals. We incorporate the consumer welfare of the plan enrollees into the PBM's objective function, analyze the PBM's copayment decision, and the equilibrium pricing behavior for competing drug manufacturers. We discuss the implications of various parameters on the equilibrium outcome for the plan enrollees, the PBM, and the drug manufacturers. We also apply our model to investigate the impact of a vertical integration of a pharmaceutical manufacturer and a PBM.

Author: Oliver Gassmann
Publisher: Springer Science & Business Media
ISBN: 3540247815
Category : Business & Economics
Languages : en
Pages : 184

View

Book Description
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.

Author: Mary Schaeffer Conroy
Publisher: Peter Lang
ISBN: 9780820478999
Category : Business & Economics
Languages : en
Pages : 394

View

Book Description
Putting privately owned Russian pharmacies and pharmaceutical factories under state control in 1918/1919 did not improve the output and the distribution of soaps, disinfectants, hormones, vitamins, and medicines. Newly available archival records show that managers appointed by the Soviet government to run sequestered factories employed business methods common to market economies to make the Soviet pharmaceutical sector profitable and productive. However, an inefficient macroeconomy and interference in day-to-day policy-making in the core industry by exogenous officials (frequent reorganization, limits on imports, and excessive exports) hindered production; this plus inefficient distribution shorted consumers. Inadequate amounts of pharmaceuticals undoubtedly contributed to high mortality during the civil war (1917-1921), collectivization and industrialization (1927-1938), and World War II (1939-1945).

Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235

View

Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.